Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Treasury Shares (2016 - 2025)

UroGen Pharma's Treasury Shares history spans 10 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 27.83% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 27.83%, while the annual FY2025 figure was $1.9 million, 27.83% up from the prior year.
  • Treasury Shares reached $1.9 million in Q4 2025 per URGN's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.9 million in Q4 2025 to a low of $690955.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: fell 8.27% in 2022, then soared 59.01% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $753274.0 in 2021, then dropped by 8.27% to $690955.0 in 2022, then soared by 59.01% to $1.1 million in 2023, then skyrocketed by 37.24% to $1.5 million in 2024, then grew by 27.83% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Treasury Shares are $1.9 million (Q4 2025), $1.5 million (Q4 2024), and $1.1 million (Q4 2023).